Author(s): Swati Rawat, Akhilesh Gupta

Email(s): swati_r@k.st

DOI: Not Available

Address: Swati Rawat1* and Akhilesh Gupta2
1Shri Bhagwan College of Pharmacy Aurangabad (M.S.)
2Kunwar Haribansh Singh College of Pharmacy Jaunpur (U.P.)
*Corresponding Author

Published In:   Volume - 1,      Issue - 1,     Year - 2011


ABSTRACT:
In this paper a brief history and an overview of the regulatory process for drug approval in the United States through illustrations of Investigational New Drug (INDs) Applications and New Drug Applications (NDAs), abbreviated new drug applications (ANDAs) and supplemental new drug applications (SNDAs) are provided. For INDs, the regulatory requirements for a well-designed protocol, the role and responsibility of institutional review boards, and the applicability of treatment INDs are discussed. For NDAs, issues regarding the application of expanded access, the submission of abbreviated NDAs for a generic drug, the submission of supplemental NDAs for labeling changes, and the role and responsibility of advisory committees are addressed. Along with this a brief description of review steps taken by FDA is provided.


Cite this article:
Swati Rawat, Akhilesh Gupta. Regulatory Requirements for Drug Development and Approval in United States: A Review. Asian J. Pharm. Res. 1(1): Jan.-Mar. 2011; Page 01-06.

Cite(Electronic):
Swati Rawat, Akhilesh Gupta. Regulatory Requirements for Drug Development and Approval in United States: A Review. Asian J. Pharm. Res. 1(1): Jan.-Mar. 2011; Page 01-06.   Available on: https://asianjpr.com/AbstractView.aspx?PID=2011-1-1-1


Recomonded Articles:

Author(s): Swati Rawat, Akhilesh Gupta

DOI:         Access: Open Access Read More

Author(s): Thakur Abhimanyu, Kondru Sushmita, Kamilya Shruti, Kumar Amit, Goldar Epshita

DOI: 10.5958/2231-5691.2015.00017.9         Access: Open Access Read More


Recent Articles




Tags